Although conventional cognitive assessments have historically proven useful for clinical practice and have aided in longitudinal research studies, the extent of their utility has been questioned, particularly as the field advances in its efforts to measure pre-clinical manifestations of AD that correlate with biomarkers of amyloid, tau and/or neurodegeneration [9]. The gene discussed is MAPT; the disease is Alzheimer disease.